Poliscio Analytics LLC
  • Daily Alerts
  • Insights
    • Our Insights Articles
    • Project 2025
  • FOIAengine
    • Log In
    • About FOIAengine
    • Trial User Signup
    • User Support
    • How to Use
  • FOIA Services
  • About
    • About PoliScio
    • Leadership
    • Newsroom
  • Contact
Select Page
When Wall Street’s Watchdogs Become the Suspects

When Wall Street’s Watchdogs Become the Suspects

by John A. Jenkins | Nov 16, 2026 | FOIA, Stock Market

FOIAengine:  New Questions About Super Micro, Nvidia, and Andrew Left’s Fraud Conviction Expose the Uneasy Relationship Between Activist Short Sellers and Prosecutors  Andrew Left, one of Wall Street’s best-known short sellers, faces up to 25 years in...
How Hedge Funds Use FOIA to Track FDA’s Regulatory Aftermath

How Hedge Funds Use FOIA to Track FDA’s Regulatory Aftermath

by John A. Jenkins | Aug 5, 2026 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Stock Market

FOIAengine: Requests from Point72, Sofinnova, Holocene, Triple Gate and Others A review of the latest Freedom of Information Act requests targeting three life-sciences companies – Novo Nordisk (NYSE: NVO); Charles River Laboratories (NYSE: CRL); and iRhythm...
When Wall Street’s Watchdogs Become the Suspects

After Andrew Left, Short Sellers Face a New Question: Who’s Next?

by John A. Jenkins | Jun 17, 2026 | FOIA, Hedge Funds, SEC, Short-Selling, Stock Market

FOIA Requests Offer Signals, and a Requester Provides Names Activist short seller Andrew Left always had a taste for risk.  So, with his freedom and fortune on the line a few weeks ago in a Los Angeles courtroom, Left tried to beat the federal securities fraud charges...
How Requesters Use FOIA to Asses Biopharma Risks

How Requesters Use FOIA to Asses Biopharma Risks

by Randy Miller | May 6, 2026 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Short-Selling, Stock Market

FOIAengine: Assessments Include Operational, Clinical and Commercial Threats Freedom of Information Act requests to the Food and Drug Administration during March illustrated three of the primary uncertainties facing U.S. drug manufacturers and their investors: the...
How Requesters Use FOIA to Asses Biopharma Risks

Beta Bionics: The Rise and Decline of a High-Flying IPO

by John A. Jenkins | Apr 9, 2026 | FDA, FOIA, Litigation, Medical Devices, Short-Selling, Stock Market

How FOIA Requests Signaled Problems With a “Bionic Pancreas”  At a federal advisory panel meeting in 2018, a biomedical engineer named Ed Damiano stepped to the microphone – not just as a scientist. “I’m also a father,” he told regulators, describing his son’s...
Emergent Biosolutions, Insider Trading, and the Gemba Shuffle

Emergent Biosolutions, Insider Trading, and the Gemba Shuffle

by John A. Jenkins | Feb 4, 2026 | FDA, FOIA, Litigation, Pharmaceuticals, Stock Market

FOIAengine: Media Requests Were Warnings, Months Before Bad News Hit In the early days of the Covid pandemic, there was big money on the line as pharmaceutical companies scrambled to produce vaccines.  The world needed a miracle.  The companies that could deliver it...
« Older Entries
  • Terms of Service
  • Privacy Policy
  • Text-to-Speech
Copyright 2026 PoliScio Analytics LLC